Screening for prostate cancer

被引:140
作者
Frankel, S
Smith, GD
Donovan, J
Neal, D
机构
[1] Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England
[2] Addenbrookes Hosp, Ctr Oncol, Cambridge, England
关键词
D O I
10.1016/S0140-6736(03)12890-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Epidemiologically, screening is,justified by the importance of the disease and the lack of prospects for primary prevention, but evidence from natural history is unhelpful since men are more likely to die with, rather than from, prostate cancer. The available screening tests do not always detect men whose lesions could result in future morbidity or mortality. Evidence is limited for the benefits of treatment for localised cancers detected through screening, whereas the evidence for harm is clear. Observational evidence for the effect of population screening programmes is mixed, with no clear association between intensity of screening and reduced prostate cancer mortality. Screening for prostate cancer cannot be justified in low-risk populations, but the balance of benefit and harm will be more favourable after risk stratification. Prostate cancer screening can be justified only in research programmes designed to assess its effectiveness and help identify the groups who may benefit.
引用
收藏
页码:1122 / 1128
页数:7
相关论文
共 88 条
[1]   Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer [J].
Albertsen, PC ;
Hanley, JA ;
Gleason, DF ;
Barry, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11) :975-980
[2]   A comparison of cause of death determination in men previously diagnosed with prostate cancer who died in 1985 or 1995 [J].
Albertsen, PC ;
Walters, S ;
Hanley, JA .
JOURNAL OF UROLOGY, 2000, 163 (02) :519-523
[3]   LONG-TERM SURVIVAL AMONG MEN WITH CONSERVATIVELY TREATED LOCALIZED PROSTATE-CANCER [J].
ALBERTSEN, PC ;
FRYBACK, DG ;
STORER, BE ;
KOLON, TF ;
FINE, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (08) :626-631
[4]  
Alexander FE, 1999, PROSTATE, V40, P135
[5]  
*AM UR SOC, 1992, EX COMM REP
[6]   The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population [J].
Bangma, CH ;
Rietbergen, JBW ;
Kranse, R ;
Blijenberg, BG ;
Petterson, K ;
Schroder, FH .
JOURNAL OF UROLOGY, 1997, 157 (06) :2191-2196
[7]   Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria [J].
Bartsch, G ;
Horninger, W ;
Klocker, H ;
Reissigl, A ;
Oberaigner, W ;
Schönitzer, D ;
Severi, G ;
Robertson, C ;
Boyle, P .
UROLOGY, 2001, 58 (03) :417-424
[8]  
Boer R, 1999, PROSTATE, V40, P130
[9]   Screening populations at low risk carries high risks [J].
Bonneux, L .
BRITISH MEDICAL JOURNAL, 2003, 326 (7379) :53-53
[10]   Cancer - The molecular outlook [J].
Caldas, C ;
Aparicio, SAJ .
NATURE, 2002, 415 (6871) :484-485